R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy

Jeffrey L. Halaas, Craig Moskowitz, Steven Horwitz, Carol Portlock, Ariela Noy, David Straus, Owen A. O'Connor, Joachim Yahalom, Andrew D. Zelenetz

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Treatment of diffuse large B-cell lymphoma (DLBCL) with CHOP-21 (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg for 5 days every 21 days) results in long-term remission in approximately 45% of patients. Recent phase III trials have demonstrated improved survival by modifying CHOP either through adding rituximab or shortening the time between cycles to 14 days. These studies prompted our institution to treat newly diagnosed patients with DLBCL refusing or not eligible for protocol-based therapy with R-CHOP-14. In this single-institution retrospective analysis, we report our results with this regimen. Forty-nine patients with newly diagnosed DLBCL and ineligible or refusing protocol-based therapy were retrospectively identified. Patients were treated with 6 - 8 cycles of R-CHOP-14 given with filgrastim and prophylactic antibiotics. The main toxicities with R-CHOP-14 were hematological and neurological and were not unexpected. There were no treatment-related deaths. Patients received 90% of planned cytotoxic drug density. The complete remission/complete remission uncertain (CR/CRu) rate was 82.2%. At a median follow-up of 24 months, the event-free survival was 80% and overall survival 90%. These results demonstrate R-CHOP-14 can be given to patients safely and short-term results regarding survival are promising. Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies.

Original languageEnglish (US)
Pages (from-to)541-547
Number of pages7
JournalLeukemia and Lymphoma
Volume46
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Survival
Vincristine
Therapeutics
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Aggressive
  • Chemotherapy
  • Dose density
  • Lymphoma
  • Retrospective
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

R-CHOP-14 in patients with diffuse large B-cell lymphoma : Feasibility and preliminary efficacy. / Halaas, Jeffrey L.; Moskowitz, Craig; Horwitz, Steven; Portlock, Carol; Noy, Ariela; Straus, David; O'Connor, Owen A.; Yahalom, Joachim; Zelenetz, Andrew D.

In: Leukemia and Lymphoma, Vol. 46, No. 4, 01.04.2005, p. 541-547.

Research output: Contribution to journalArticle

Halaas, JL, Moskowitz, C, Horwitz, S, Portlock, C, Noy, A, Straus, D, O'Connor, OA, Yahalom, J & Zelenetz, AD 2005, 'R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy', Leukemia and Lymphoma, vol. 46, no. 4, pp. 541-547. https://doi.org/10.1080/10428190400029932
Halaas, Jeffrey L. ; Moskowitz, Craig ; Horwitz, Steven ; Portlock, Carol ; Noy, Ariela ; Straus, David ; O'Connor, Owen A. ; Yahalom, Joachim ; Zelenetz, Andrew D. / R-CHOP-14 in patients with diffuse large B-cell lymphoma : Feasibility and preliminary efficacy. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 4. pp. 541-547.
@article{893df3744dfc4dc8a143a4458027ce44,
title = "R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy",
abstract = "Treatment of diffuse large B-cell lymphoma (DLBCL) with CHOP-21 (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg for 5 days every 21 days) results in long-term remission in approximately 45{\%} of patients. Recent phase III trials have demonstrated improved survival by modifying CHOP either through adding rituximab or shortening the time between cycles to 14 days. These studies prompted our institution to treat newly diagnosed patients with DLBCL refusing or not eligible for protocol-based therapy with R-CHOP-14. In this single-institution retrospective analysis, we report our results with this regimen. Forty-nine patients with newly diagnosed DLBCL and ineligible or refusing protocol-based therapy were retrospectively identified. Patients were treated with 6 - 8 cycles of R-CHOP-14 given with filgrastim and prophylactic antibiotics. The main toxicities with R-CHOP-14 were hematological and neurological and were not unexpected. There were no treatment-related deaths. Patients received 90{\%} of planned cytotoxic drug density. The complete remission/complete remission uncertain (CR/CRu) rate was 82.2{\%}. At a median follow-up of 24 months, the event-free survival was 80{\%} and overall survival 90{\%}. These results demonstrate R-CHOP-14 can be given to patients safely and short-term results regarding survival are promising. Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies.",
keywords = "Aggressive, Chemotherapy, Dose density, Lymphoma, Retrospective, Rituximab",
author = "Halaas, {Jeffrey L.} and Craig Moskowitz and Steven Horwitz and Carol Portlock and Ariela Noy and David Straus and O'Connor, {Owen A.} and Joachim Yahalom and Zelenetz, {Andrew D.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1080/10428190400029932",
language = "English (US)",
volume = "46",
pages = "541--547",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - R-CHOP-14 in patients with diffuse large B-cell lymphoma

T2 - Feasibility and preliminary efficacy

AU - Halaas, Jeffrey L.

AU - Moskowitz, Craig

AU - Horwitz, Steven

AU - Portlock, Carol

AU - Noy, Ariela

AU - Straus, David

AU - O'Connor, Owen A.

AU - Yahalom, Joachim

AU - Zelenetz, Andrew D.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Treatment of diffuse large B-cell lymphoma (DLBCL) with CHOP-21 (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg for 5 days every 21 days) results in long-term remission in approximately 45% of patients. Recent phase III trials have demonstrated improved survival by modifying CHOP either through adding rituximab or shortening the time between cycles to 14 days. These studies prompted our institution to treat newly diagnosed patients with DLBCL refusing or not eligible for protocol-based therapy with R-CHOP-14. In this single-institution retrospective analysis, we report our results with this regimen. Forty-nine patients with newly diagnosed DLBCL and ineligible or refusing protocol-based therapy were retrospectively identified. Patients were treated with 6 - 8 cycles of R-CHOP-14 given with filgrastim and prophylactic antibiotics. The main toxicities with R-CHOP-14 were hematological and neurological and were not unexpected. There were no treatment-related deaths. Patients received 90% of planned cytotoxic drug density. The complete remission/complete remission uncertain (CR/CRu) rate was 82.2%. At a median follow-up of 24 months, the event-free survival was 80% and overall survival 90%. These results demonstrate R-CHOP-14 can be given to patients safely and short-term results regarding survival are promising. Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies.

AB - Treatment of diffuse large B-cell lymphoma (DLBCL) with CHOP-21 (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg for 5 days every 21 days) results in long-term remission in approximately 45% of patients. Recent phase III trials have demonstrated improved survival by modifying CHOP either through adding rituximab or shortening the time between cycles to 14 days. These studies prompted our institution to treat newly diagnosed patients with DLBCL refusing or not eligible for protocol-based therapy with R-CHOP-14. In this single-institution retrospective analysis, we report our results with this regimen. Forty-nine patients with newly diagnosed DLBCL and ineligible or refusing protocol-based therapy were retrospectively identified. Patients were treated with 6 - 8 cycles of R-CHOP-14 given with filgrastim and prophylactic antibiotics. The main toxicities with R-CHOP-14 were hematological and neurological and were not unexpected. There were no treatment-related deaths. Patients received 90% of planned cytotoxic drug density. The complete remission/complete remission uncertain (CR/CRu) rate was 82.2%. At a median follow-up of 24 months, the event-free survival was 80% and overall survival 90%. These results demonstrate R-CHOP-14 can be given to patients safely and short-term results regarding survival are promising. Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies.

KW - Aggressive

KW - Chemotherapy

KW - Dose density

KW - Lymphoma

KW - Retrospective

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=17844381640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844381640&partnerID=8YFLogxK

U2 - 10.1080/10428190400029932

DO - 10.1080/10428190400029932

M3 - Article

C2 - 16019482

AN - SCOPUS:17844381640

VL - 46

SP - 541

EP - 547

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -